Advice

following a full submission:

dimethyl fumarate (SkilarenceĀ®) is accepted for restricted use within NHS Scotland.

Indication under review: for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.

SMC restriction: for use in patients in whom other non-biologic systemic treatments (methotrexate, ciclosporin and acitretin) are not appropriate or have failed and who are considered unsuitable for biologic therapy given their current disease state or personal preference.

In a 16 week, double-blind, phase III study, dimethyl fumarate was superior to placebo and non-inferior to a fumaric acid ester product at improving the symptoms of moderate to severe plaque psoriasis in adults.

Download detailed advice236KB (PDF)

Download

Medicine details

Medicine name:
dimethyl fumarate (Skilarence)
SMC ID:
1313/18
Indication:
Treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.
Pharmaceutical company
Almirall Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Restricted
Date advice published:
09 April 2018